Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.45 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.45 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TXN | P10599 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361622 | 0.90 | NPSR1 (0.51) | NPSR1DDAH1NPC1RAB9ABCHE | |
| SCHEMBL14361831 | 0.88 | NPSR1 (0.49) | NPSR1DDAH1NPC1RAB9ABCHE | |
| SCHEMBL14361607 | 0.87 | NPSR1 (0.54) | NPSR1DDAH1NPC1RAB9ABCHE | |
| SCHEMBL13073559 | 0.86 | NPSR1 (0.58) | NPSR1DDAH1NPC1RAB9ABCHE | |
| SCHEMBL20476291 | 0.85 | NPSR1 (0.53) | NPSR1DDAH1NPC1RAB9ACYP1A2 | |
| SCHEMBL22016725 | 0.81 | NPSR1 (0.56) | NPSR1DDAH1NPC1RAB9ABCHE | |
| SCHEMBL22017306 | 0.80 | NPSR1 (0.44) | NPSR1DDAH1NPC1RAB9ABCHE | |
| SCHEMBL229852 | 0.80 | NPSR1 (0.68) | NPSR1DDAH1NPC1RAB9ACYP1A2 | |
| SCHEMBL23452588 | 0.80 | KDM4C (0.38) | NPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL27484748 | 0.80 | NPSR1 (0.50) | NPSR1DDAH1NPC1RAB9ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220273634-A1 | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) | VIFOR (INTERNATIONAL) AG (CH) | 2022-09-01 | — | — | US | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273634-A1 | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) | SLC40A1, FECH, TFRC | NPSR1 4585/4885DDAH1 1052/4885NPC1 1163/4885 |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | NPSR1 4847/4885DDAH1 2760/4885NPC1 3220/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | NPSR1 4847/4885DDAH1 2760/4885NPC1 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.